The Investor
08 Jan 2026, 06:18
AbbVie Inc. updated its 2025 guidance to reflect acquired IPR&D and milestone expenses recorded in the fourth quarter.
For Q4 2025, AbbVie reported $1.27 billion in acquired IPR&D and milestone expenses, reducing adjusted diluted EPS by $0.71. As a result, adjusted diluted EPS guidance for the quarter was lowered to a range of $2.61–$2.65.
For the full year 2025, the same $1.27 billion expense reduced adjusted diluted EPS by $0.71, bringing full-year adjusted diluted EPS guidance to $9.90–$9.94, compared with the prior range of $10.61–$10.65.
For Q4 2025, AbbVie reported $1.27 billion in acquired IPR&D and milestone expenses, reducing adjusted diluted EPS by $0.71. As a result, adjusted diluted EPS guidance for the quarter was lowered to a range of $2.61–$2.65.
For the full year 2025, the same $1.27 billion expense reduced adjusted diluted EPS by $0.71, bringing full-year adjusted diluted EPS guidance to $9.90–$9.94, compared with the prior range of $10.61–$10.65.